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Increases in intracellular free Ca2+ play a 
major role in many cellular processes. The 
deregulation of Ca2+ signaling is a feature of a 
variety of diseases and modulators of Ca2+ 
signaling are used to treat conditions as 
diverse as hypertension to pain. The Ca2+ 
signal also plays a role in processes important 
in cancer such as proliferation and migration. 
Many studies in cancer have identified 
alterations in the expression of proteins 
involved in the movement of Ca2+ across the 
plasma membrane and sub-cellular 
organelles. In some cases these Ca2+ channels 
or pumps are potential therapeutic targets for 
specific cancer subtypes or correlate with 
prognosis.  
 
Our understanding of calcium signaling and its 
intersection with specific processes important in 
tumor progression is only recent. We now 
appreciate that altered expression of specific 
Ca2+ channels and pumps is a characterizing 
feature of some cancers. By comparison, the link 
between calcium signaling and other conditions 
such as cardiovascular and neurological diseases 
was made many years ago. The direct link 
between Ca2+ and processes linked to a specific 
pathology, such as vascular tone and 
neurotoxicity, meant that these conditions 
attracted the initial focus of researchers devoted 
to defining the role of Ca2+ in disease.  
 
In their seminal review “The hallmarks of 
cancer” Hanahan and Weinberg (1) described six 
acquired characteristics of cancers: the ability to 
evade apoptosis, self-sufficiency in growth 
signaling, insensitivity to anti-growth signals, 
the capacity to invade and metastasize, 
“limitless” replication potential and the 
promotion of angiogenesis. Calcium signaling is 
linked either directly or indirectly to each of 
these processes and this has been reviewed 
elsewhere (2-6). A remodeling of calcium 
homeostasis can occur in cancer cells. Although 
alterations in Ca2+ signaling may not be a 
requirement for the initiation of cancer, the 
consequences of altered calcium transport in 
cancer cells may be significant and contribute to 
tumor progression. Characterizing such changes 
may help to identify new therapeutic targets. In 
this review we will discuss how remodeling of 
Ca2+ signaling is a feature of some cancers and 
provide examples of how this remodeling is 
often achieved through the differential 
expression of specific Ca2+ pumps and channels. 
Examples of this remodeling are discussed, 
particularly those that illustrate the complexities 
of expression changes and their contribution to 
tumor progression.  
 
Ca2+ transport in cancer cells 
 
Cancer cells use the same calcium channels, 
pumps and exchangers as non-malignant cells. 
However, there are often key alterations in 
calcium channels and pumps in cancer cells. 
Such changes in cancer cells may include:  the 
expression of calcium channels or pumps (or 
their specific isoforms) not normally present in 
non-malignant cells of the same cell type, 
pronounced changes in the level of expression 
(as outlined in Table 1), altered cellular 
localization, altered activity through changes in 
2	   [Type	  text]	  	  
	   2	  
post-translational modification, gene mutations 
and changes in activity or expression associated 
with specific cancer-relevant processes (e.g. 
migration). These changes are often reflected in 
alterations in Ca2+ flux across the plasma 
membrane or across intracellular organelles. 
 
Ca2+ influx in cancer 
 
The influx of calcium across the plasma 
membrane into the cell is a key trigger or 
regulator of cellular process relevant to tumor 
progression including proliferation, migration 
and apoptosis. Ca2+ permeable ion channels of 
almost every class have now been associated 
with aspects of tumor progression. This review 
will particularly focus on transient receptor 
potential (TRP) channels and ORAI-mediated 
store-operated Ca2+ influx as examples of Ca2+ 
influx pathways altered in some cancers. 
 
1. TRP channels 
 
TRP ion channels consist of six subfamilies, 
with most members permeable to Ca2+, many of 
which have a role in distinguishing sensations 
including pain, temperature, taste and pressure 
(7). This family is arguably the most studied ion 
channel class in cancer. The key early work on 
calcium signaling in cancer was focused on 
cancers of the prostate gland and more 
specifically the calcium permeable ion channel 
TRPM8 (8). Although now predominately 
studied in the context of its role as a cold 
receptor (9,10), TRPM8 was first identified by 
its overexpression in some prostate cancers (8). 
Early work by Zhang and Barritt (11) 
demonstrated that both the silencing of TRPM8 
and menthol-mediated activation of TRPM8 
reduced the viability of LNCaP prostate cancer 
cells. That both activators and inhibitors are 
proposed as potential therapeutic agents for 
prostate cancer cells that overexpress TRPM8 is 
reflective of the duality of the calcium signal 
(12), whereby Ca2+ is both a key regulator of 
proliferation and in the case of Ca2+ overload an 
initiator of cell death. The ability of TRPM8 
activation by prostate-specific antigen to inhibit 
the migration of PC3 prostate cancer cells now 
extends the applicability of channel activators as 
therapeutics beyond just inducers of cancer cell 
death (13). Further detailed work on TRPM8 in 
prostate cancer shows androgen-mediated 
increases in TRPM8 in LNCaP prostate cancer 
cells (11,14). This finding provides one of the 
first examples of hormone-mediated changes in 
the expression of a calcium permeable ion 
channel in a cancer cell line. As discussed later 
in this review, this has now been seen with other 
calcium channels and pumps in breast cancers. 
 
The contribution of TRPM8 to cancer 
progression, as we will see for other Ca2+ 
channels and pumps, may not always involve its 
classic role (in this case as a plasmalemmal ion 
channel). As opposed to the usual plasma 
membrane localization, endoplasmic reticulum 
localization of TRPM8 is observed in some 
prostate cancer cells (11,15) with the 
consequence being reduced levels of 
endoplasmic reticulum Ca2+ and increased 
resistance to apoptosis (15). Aside from prostate 
cancer, overexpression of TRPM8 is also 
associated with other cancer types including 
melanoma and cancers of the pancreas, breast, 
colon and lung (see Table 1). However, the 
utility of TRPM8 as a target for cancer therapy 
might be limited and require knowledge of the 
individual tumor expression of the channel. For 
example, TRPM8 expression actually appears to 
reduce as prostate cancer cells transition to 
androgen independence and increased 
aggressiveness (16,17).  
 
TRPV6 is another TRP channel linked to 
prostate cancer. TRPV6 levels correlate with 
tumor progression and have been proposed as a 
predictor of invasiveness (18,19). TRPV6 is 
highly Ca2+ selective and is constitutively active 
(20). When TRPV6 expression is silenced in 
LNCaP prostate cancer cells there is inhibition 
of Ca2+ influx and consequently reduced 
activation of NFAT. Crucially this illustrates the 
importance of calcium dependent transcription 
pathways as a mechanism for tumor promotion 
(19).  
 
Like TRPM8, alterations in TRPV6 expression 
are not confined to cancers of the prostate, with 
increased expression levels reported in thyroid, 
colon, ovarian and breast cancers (Table 1). In 
breast cancers the expression of TRPV6 varies 
widely between tumors (21). The consequences 
of TRPV6 overexpression in tumors may relate 
to effects on cancer cell survival, as TRPV6 
silencing in T47D breast cancer cells reduces 
cell viability (21). Further studies are needed to 
address the mechanisms leading to TRPV6 
overexpression in cancers and the association 
between TRPV6 levels and breast cancer 
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prognosis. Analogous to the androgen 
dependence of TRPM8 expression in LNCaP 
prostate cancer cells, TRPV6 levels also appear 
to be hormonally regulated with estradiol 
increasing TRPV6 mRNA in T47D breast cancer 
cells (21).  
 
Other examples of TRP channels that are 
overexpressed in multiple cancer types include 
TRPC3 and TRPC6. TRPC3 is elevated in some 
breast (22) and ovarian epithelial tumors, and its 
silencing reduces ovarian cancer cell line 
proliferation in vitro and tumor formation in vivo 
(23). TRPC6 is elevated in cancers of the breast, 
liver, stomach and esophageous, and in gliomas 
(22,24,25), and its silencing reduces the 
proliferation of some esophageal and breast 
cancer cell lines and glioma cell lines (22,24,25). 
For esophageal and glioma cell lines these 
effects are due to G2/M cell cycle arrest (24,25). 
 
The importance of some TRP channels in tumor 
progression appears to extend beyond the 
primary tumor. Fiorio Pla et al. (26) showed that 
migrating endothelial cells have a greater 
[Ca2+]CYT response to the TRPV4 activator 
4αPDD than non-migrating cells. Furthermore 
they showed increased expression of TRPV4 in 
endothelial cells derived from breast cancers 
compared to those derived from normal tissue, 
implicating TRPV4 as a possible key component 
in angiogenesis associated with breast cancers. 
Other Ca2+ channels have also been associated 
with angiogenesis as recently reviewed (4).  
 
Calcium entry into the cell via some TRP 
channels may result in localized Ca2+ signals that 
contribute to cancer cell migration (3). One 
example of such a localized event is referred to 
as Ca2+ flickers (27), which are highly localized 
(~ 5 µm diameter) and transient (10 ms – 4 s) 
increases in Ca2+ that control the direction of 
migration as lung fibroblasts move towards a 
growth factor. Ca2+ flickers during migration are 
regulated by TRPM7 (27), which may act as a 
stretch or mechanical sensing channel (28). With 
TRPM7 inhibition there is a reduction in 
migration of a number of cancer cell types 
including those of the pancreas, lung and 
nasopharynx (29-31). 
 
The examples above highlight some studies 
where cancer cells are associated with a 
remodeling of TRP channel expression or where 
TRP channels have been linked to specific 
processes important in tumor progression. The 
interest and understanding of TRP channels in 
cancer is likely to expand in the coming years 
and these channels may represent the first class 
of ion channel targeted for the treatment of a 
specific cancer.  
 
2. Store-operated Ca2+ influx 
 
Store-operated Ca2+ entry is a critical Ca2+ influx 
pathway and represents the major Ca2+ influx 
mechanism in non-excitable cells (32), such as 
those of the epithelia from where most cancers 
originate. The pathway involves the activation of 
Ca2+ influx upon intracellular Ca2+ store 
depletion (32-34). The canonical components of 
store-operated Ca2+ entry are the calcium influx 
channel ORAI1 and the endoplasmic Ca2+ 
depletion sensor STIM1 (35,36). While this 
pathway has rapidly become one of the Ca2+-
influx pathways most studied in breast cancer, it 
also appears to be an important Ca2+ influx route 
during lactation (37), suggesting an important 
role in normal breast function.  
 
ORAI1 and STIM1 silencing in MDA-MB-231 
breast cancer cells reduces migration, invasion 
through Matrigel and the establishment of lung 
metastasis after tail vein injection in NOD/SCID 
mice (38), the later of which can be mimicked 
by the pharmacological store-operated Ca2+ 
influx inhibitor SKF96365 (38). The anti-
metastasis effects of ORAI1 and STIM1 
silencing appear in part due to alterations in 
focal adhesion turn over (38). The effects of 
ORAI1 silencing on breast cancer cells are not 
restricted to inhibition of processes important in 
migration, ORAI1 silencing has anti-
proliferative properties in MCF-7 breast cancer 
cells in culture and in vivo. These changes may 
in part be due to reductions in basal Ca2+ influx 
leading to reduced ERK1/2 phosphorylation and 
cyclin D1 expression (39). 
 
Alterations in the expression of specific 
components of store-operated Ca2+ entry are also 
a feature of some breast cancer cells. ORAI1 
mRNA levels are higher in some breast cancer 
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cell lines compared to non-malignant breast cell 
lines (37). When breast cancer subtypes are 
stratified by gene expression, basal breast 
cancers (associated with a poor prognosis and a 
lack of effective therapies) are characterized by 
an elevated STIM1/STIM2 ratio. 
Correspondingly those patients with breast 
cancers with a high STIM1/STIM2 ratio and 
high STIM1 levels have significantly reduced 
survival (37), placing STIM proteins as either 
potential key regulators or biomarkers of breast 
cancer progression. The significance of STIM1 
may extend beyond breast cancers given its role 
in the migration of cervical cancer cells (40). 
The mechanisms responsible for enhanced 
ORAI1-mediated Ca2+ influx in breast cancer 
appear to be complex and related to cancer 
subtypes. As discussed later in this review, in 
addition to STIM1-mediated activation of 
ORAI1, some breast cancers that overexpress 
the secretory pathway Ca2+-ATPase 2 (SPCA2) 
isoform may be characterized by elevated 
ORAI1 mediated Ca2+ influx. 
 
The ORAI1 isoform is not the only ORAI 
protein with a cancer association. ORAI3 protein 
levels and ORAI3-dependent store-operated Ca2+ 
influx are both elevated in estrogen receptor 
positive breast cancer cell lines (41) compared to 
estrogen receptor negative cell lines where store-
operated Ca2+ influx is predominately mediated 
by ORAI1. A strengthening of the causative link 
with cancer was provided by a study in estrogen 
receptor positive MCF-7 breast cancer cells 
where ORAI3 silencing inhibited proliferation 
through G1 arrest (42). Although the examples 
above point to an upregulation of ORAI-
mediated influx, some cancer types might be 
associated with a down regulation of this 
pathway that may in turn help in the acquisition 
of apoptotic resistance (6). Indeed, reduced 
ORAI1-mediated Ca2+ influx and expression is a 
feature of androgen independent prostate cancer 
cells, and silencing of ORAI1 reduces apoptosis 
in LNCaP cells (43).  
 
This review has given examples of how ORAI1 
may regulate processes important for 
carcinogenesis, including cell proliferation, 
migration and apoptosis sensitivity, and this may 
occur in a store-dependent or -independent 
manner. Examples of how ORAI1 regulates 
these key cancer processes are shown 
schematically in Figure 1. 
 
Although not a focus of this review voltage-
gated calcium channels are increasingly studied 
in cancer and in many cases the studies have 
examined the reasons for changes in expression 
levels in cancer. This is particularly illustrated in 
studies assessing mechanisms of altered 
expression of voltage-gated ion channels. For 
example, higher relapse in Wilms’ tumors is 
associated with higher DNA copy numbers of 
the α1 subunit of the voltage-gated Ca2+ channel 
CACNA1E (44) and reduced expression of 
CACNA2D3 via promotor hypermethylation is 
associated with poor prognosis in gastric cancer 
(45). These methodological approaches will be 
applied to other channels and pumps and other 
cancers in the future.  
 
Ca2+ efflux in cancer 
 
Ca2+ efflux across the plasma membrane can be 
mediated by both Na+/Ca2+ exchangers and 
primary active transport via plasma membrane 
Ca2+-ATPases (PMCAs). However, most studies 
of Ca2+ efflux pathways in cancer cells have 
focused on the latter mechanism. PMCAs are 
encoded by 4 genes (PMCA1-4), which are 
alternatively spliced to generate a suite of Ca2+ 
efflux pumps responsible for maintaining resting 
cytosolic free Ca2+ at low (~ 100 nM) levels 
(46,47). PMCAs also contribute to specific cell 
functions, such as the transport of Ca2+ into milk 
through PMCA2 (48). 
 
An area where PMCAs may be critically 
important in cancer is the regulation of cell 
death, as reflected in early work assessing the 
consequences of PMCA overexpression. 
Overexpression of some PMCA isoforms in 
CHO cells reduces Ca2+ levels within the 
endoplasmic reticulum and also attenuates 
mitochondrial Ca2+ accumulation after cell 
activation (49), a consequence which would be 
hypothesized to result in anti-apoptotic effects. 
Indeed, the overexpression of PMCA in HeLa 
cells increases their resistance to cell death 
induced by ceramide (50). Recent studies in 
T47D breast cancer cells shows that the 
overexpression of PMCA2 reduces the degree of 
cell death induced by ionomycin and this is 
associated with a reduction in the duration and 
magnitude of increases in [Ca2+]CYT mediated by 
this Ca2+ ionophore (51). PMCA2 is an isoform 
with reported overexpression in some breast 
cancer cell lines (52) and in clinical human 
samples, where high levels appear to be 
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associated with a poor prognosis in some patient 
groups (51). Collectively these studies suggest 
that the remodeling of calcium efflux associated 
with increases in PMCA expression contributes 
to the acquisition of an anti-apoptotic phenotype 
in cancer cells. 
 
Studies assessing the expression of PMCA 
isoforms during the differentiation of colon 
cancer cells suggest that a remodeling of PMCA 
isoform expression is not confined to cancers of 
the breast. PMCA1 expression remains fairly 
constant during differentiation of human colon 
cancer cell lines, whereas PMCA4 undergoes a 
pronounced increase in expression with 
differentiation (53,54). PMCA4 overexpression 
studies in HT29 colon cancer cells suggests that 
the down regulation of PMCA4 in colon cancer 
may help to augment [Ca2+]CYT responses to 
proliferative stimuli without sufficiently 
increasing [Ca2+]CYT to levels that promote 
apoptosis (55). The changes in PMCA4 
expression seen in the differentiation models 
correlate well with human colon cancer clinical 
samples, where PMCA4 mRNA is reduced in 
colon adenocarcinomas compared to normal 
colon (55). The upregulation of PMCA2 
expression in breast cancer and the down 
regulation of PMCA4 in colon cancer may seem 
conflicting, however, in both cases the changes 
in PMCA expression appear to bestow an 
advantage to the cancer cell, in the case of 
PMCA2 in breast cancer cells this appears to be 
related to the acquisition of greater resistance to 
cell death, and in colon cancer cells augmented 
responses to proliferative signals.  
 
Intracellular organelle Ca2+ channels and 
pumps and cancer 
 
Intracellular organelles play critical roles in 
Ca2+-regulated processes either through the 
regulation of cytosolic free Ca2+ or through 
modulation of Ca2+ regulated proteins that reside 
within the organelle. This review will outline 
examples of Ca2+ channels and pumps of the 
endoplasmic reticulum and Golgi as these have 
been the most studied in cancer. However, the 
recent identification of proteins that play major 
roles in mitochondrial Ca2+ influx and efflux 
(56-58) and the recently identified two pore 
channel proteins present in endosomes (TPC1) 
and lysosomes (TPC2) (59) represent new 
opportunities to improve our understanding of 
the remodeling of Ca2+ signaling in some 
cancers and will no doubt be the focus of 
research in the future (60).  
 
Regulators of endoplasmic reticulum Ca2+ 
levels 
 
One of the earliest links between the regulation 
of endoplasmic reticulum Ca2+ and cancer comes 
from studies of the anti-apoptotic protein Bcl-2 
(B cell lymphoma-2). In addition to its early and 
now well-established role in inhibiting the 
release of the pro-apoptotic factor cytochrome c 
(61-63), Bcl-2 decreases the Ca2+ content of the 
endoplasmic reticulum (50,64,65). 
Mechanistically this occurs at least in part 
through interaction with the IP3 receptor (66), 
likely reducing the ability to achieve the high 
Ca2+ loads required for mitochondria to 
accumulate Ca2+ sufficiently to trigger apoptotic 
cell death (67). Some examples of alterations in 
the expression of key calcium channels and 
pumps of the endoplasmic reticulum are 
highlighted in Table 1. Similar to increases in 
the expression of PMCA4 during colon cancer 
cell line differentiation and the down regulation 
of PMCA4 expression in some colon cancers, 
SERCA3 pump expression increases with the 
differentiation of colon cell lines, and is down 
regulated in colon cancer (68), implicating a 
major remodeling of active Ca2+ transport in 
colon cancer. The significance of the down 
regulation of SERCA3 is not restricted to colon 
cancer, given the more recent report of a 
significant down regulation of SERCA3 in 
breast cancers, an event that is even seen in 
benign lesions (69).  Further evidence of the 
potential significance of SERCA down 
regulation in cancer is reflected in studies of 
mice haplodeficient for SERCA2 (70,71). These 
mice are characterized by increased incidence of 
squamous cell tumors, the mechanism of which 
likely involves altered Ca2+ signaling and a 
subsequent change in the microenvironment of 
skin epithelia (70).  
 
Regulators of Golgi Ca2+ levels 
 
Although more recently identified and less 
widely studied in the context of contributions to 
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cellular processes than SERCAs, secretory 
pathway Ca2+-ATPases (SPCAs), both the 
ubiquitously expressed SPCA1 isoform and the 
more restricted SPCA2 isoform (72,73), are 
beginning to be assessed in cancer cells.  
 
In MDA-MB-231 basal-like breast cancer cells 
(that do not express the SPCA2 isoform), 
SPCA1 silencing inhibits proliferation without 
changes in global [Ca2+]CYT, consistent with the 
minor role of SPCAs (c.f. PMCAs and SERCAs) 
in contributing to [Ca2+]CYT recovery in most cell 
types (74). Instead, as may be the case for other 
Ca2+ channels and pumps located on the 
membranes of intracellular organelles, the 
mechanism by which SPCA1 silencing inhibits 
proliferation may involve alterations in the Ca2+ 
levels within the Golgi lumen where Ca2+ 
regulated enzymes reside. Indeed, one 
consequence of SPCA1 silencing in MDA-MB-
231 breast cancer cells is the inhibition of 
cleavage of pro-IGF1R likely through reduced 
activity of the Ca2+-sensitive pro-protein 
convertase Furin (74). The consequences of 
reduced SPCA1-mediated Ca2+ sequestration 
may be cell type and context dependent as 
shown by the increased susceptibility of Spca1+/- 
mice to develop squamous skin tumors (75). 
 
One of the proposed roles for the other secretory 
pathway Ca2+ ATPase isoform, SPCA2, has been 
the sequestration of Ca2+ during lactation (76), 
however, this pump also appears to play a role in 
the pathophysiology of breast cancer. SPCA2 
levels are increased in luminal-like breast cancer 
cell lines and clinical breast cancers belonging to 
the Luminal B and ERBB2 molecular subtypes 
(39). This may be related to hormonal factors 
given that in MCF-7 breast cancer cells SPCA2 
mRNA levels increase with prolactin (77).   
Silencing of SPCA2 in breast cancer cell lines 
that overexpress this Ca2+ pump, such as MCF-7 
cells, reduces their proliferation, anchorage 
independent growth and growth in vivo (39).  
However, in contrast to SPCA1 in breast cancer 
cells, SPCA2 does not appear to contribute to 
tumor progression through alterations in Ca2+ 
levels within the Golgi. In a result which was 
initially counter intuitive, SPCA2 
overexpression increases basal [Ca2+]CYT, rather 
than decreasing it as might be expected for a 
calcium pump that sequesters Ca2+ from the 
cytoplasm into the Golgi. Overexpression of 
SPCA2 leads to its localization at the plasma 
membrane where it activates ORAI1 channels, 
the consequence of which is activation of the 
transcription factor NFAT (shown in Figure 1A) 
(39). SPCA2 overexpression-induced increases 
in Ca2+ influx across the plasma membrane 
represents an example where the contribution 
that a calcium pump makes to tumor progression 
is not directly related to its own Ca2+ 
transporting ability. The ability of SPCA2 to 
contribute to tumor growth independently of its 
own Ca2+ transporting ability suggests that 
pharmacological inhibitors of SPCA2 Ca2+ 
transport function may be ineffective in breast 
cancers where SPCA2 solely contributes to 
tumor growth through this ORAI1-dependent 
mechanism and demonstrates the importance of 
mechanistic studies assessing the contribution of 
Ca2+ channels and pumps to tumorigenic 
pathways. 
 
Calcium signaling and cancer – new horizons 
 
Major advances have occurred in the last decade 
in our understanding of how calcium signaling is 
remodeled in some cancer cells and how specific 
calcium channels or pumps represent potential 
new therapeutic targets in oncology. However, 
there are areas of cancer research where the link 
between calcium signaling is still relatively 
unexplored, such as the “emerging hallmarks of 
cancer” recently described by Hanahan and 
Weinberg (78). These include cellular energy 
metabolism reprogramming, whereby cancer 
cells shift their energy metabolism to glycolysis, 
a phenomenon first described by Otto Warburg 
almost a century ago (78-80). Further studies on 
the possible role of Ca2+ signaling in the 
regulation of glycolysis, the switch to glycolysis 
and the use of glycolysis generated ATP to fuel 
Ca2+ pumps in cancer cells is required (81,82). 
Another aspect of cancer biology where Ca2+ 
signaling is clearly going to be critical but has 
not been fully explored is the tumor 
microenvironment (78). Due to the depth of 
work in the area of tumor microenvironment 
readers are encouraged to consult the numerous 
reviews on this topic (83-85). An aspect of the 
tumor microenvironment where signaling is 
likely to be particularly significant is cancer 
associated fibroblasts, which are in an 
“activated” state and are in a dynamic signaling 
interplay with cancer cells (78,86). Ca2+ may be 
critical to this signaling as reflected by the 
importance of PDGF in the signaling between 
cervical cancer cells and cancer associated 
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fibroblasts (87) and the ability of PDGF to 
elevate [Ca2+]CYT in other cell types (88). 
 
Conclusions 
Many processes contribute to cancer 
development and Ca2+ signaling seems to play a 
role in many of them. Numerous studies have 
now established that some cancers are associated 
with major changes in the expression of specific 
Ca2+ channels and pumps, and that inhibition of 
some of these proteins inhibits the proliferation 
and/or metastasis of cancer cells. The next 
decade will see the role of Ca2+ in cancer further 
defined and may see agents that specifically 
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Figure 1—ORAI1 regulates processes important for cancer cell proliferation, migration and 
apoptosis.  
A) In MCF7 human breast cancer cells SPCA2 partially localizes to the plasma membrane and 
interacts with ORAI1 to mediate store-independent Ca2+ influx. This is associated with 
phosphorylation of extracellular signal-regulated kinase-1/2, nuclear translocation of NFAT and 
increased cell proliferation (39). B) Silencing of ORAI1 or STIM1 in MDA-MB-231 human breast 
cancer cells reduces store-operated Ca2+ influx and is associated with reduced focal adhesion turnover, 
cell migration and metastasis formation in vivo. Expression of constitutively active Ras or Rac in 
these cells partially rescues impaired focal adhesion turnover and cell migration induced by inhibition 
of store-operated Ca2+ entry, implicating possible roles for these small GTPases in Ca2+-dependent 
cell migration (39). C) In LNCaP human prostate cancer cells ORAI1 expression is regulated by the 
androgen receptor (AR) and ORAI1 silencing is associated with resistance to thapsigargin (TG), 
tumor necrosis factor α (TNFα), cisplatin and oxaliplatin -induced apoptosis (43). In panel A and B 
(black) ORAI1 expression may promote carcinogenesis; in panel C (red) ORAI1 expression may 
inhibit carcinogenesis (i.e. promote apoptosis). 
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Table 1: Examples of altered expression of calcium channels and pumps in human cancers 
Ca2+ pump 
or channel   Cancer type 
Change with cancer 
Reference mRNA Protein 
Transient receptor potential channels 
TRPC1 Breast cancer: patient tissue samples ↑ ↑ (89) 
TRPC3 Ovarian cancer: patient tissue samples  ↑ (23) 
Breast cancer: patient tissue samples ↑  (22) 
TRPC6 Esophageal cancer: patient tissue samples ↑ ↑ (24) 
Glioma: patient tissue samples ↑ ↑ (25) 
Liver cancer: patient tissue samples ↑ ↑ (90) 
Breast cancer: patient tissue samples ↑ ↑ (22,89) 
TRPM7 Pancreatic cancer: patient tissue samples ↑ ↑ (29) 
Breast cancer: patient tissue samples ↑ ↑ (89) 
TRPM8 Pancreatic cancer: cell lines (mRNA) & patient tissue samples (protein) ↑ ↑ (91) 
Prostate cancer: cell lines & patient tissue samples ↑ ↑ (8,17,92) 
Breast cancer: patient tissue samples ↑ ↑ (8,89) 
Melanoma: patient tissue samples ↑  (8) 
Colorectal cancer: patient tissue samples ↑  (8) 
Lung cancer: patient tissue samples ↑  (8) 
TRPV1 Bladder cancer: patient tissue samples ↓ ↓ (93) 
Prostate cancer: patient tissue samples ↑ ↑ (94) 
TRPV6 Breast cancer: patient tissue samples ↑ ↑ (18,21,89,95) 
Prostate cancer: patient tissue samples ↑ ↑ (18,95) 
Thyroid cancer: patient tissue samples  ↑ (95) 
Colon cancer: patient tissue samples  ↑ (95) 
Ovarian cancer: patient tissue samples  ↑ (95) 
Voltage-gated calcium channels 
Cav1.2 Colon cancer: patient tissue samples ↑  (96) 
Cav3.2 Prostate cancer: patient tissue samples ↔ ↑ (97) 
Store-operated calcium channels 
ORAI1 Breast cancer: cell lines ↑ ↔ (37,41) 
ORAI3 Breast cancer: cell lines & patient tissue samples (mRNA only) ↑, ↔ ↑ (37,41,42) 
Plasma membrane calcium ATPases 
PMCA2 Breast cancer: cell lines (mRNA only) & patient tissue samples ↑ ↑ (51,52) 
PMCA4 Colon cancer: patient tissue samples ↓  (55) 
Store release channels 
IP3R1 Glioblastoma: patient tissue samples ↓  (98) 
IP3R3 Glioblastoma: patient tissue samples ↑  (98) 
Colorectal cancer: patient tissue samples  ↑ (99) 
Sarcoplasmic/endoplasmic reticulum calcium ATPases 
SERCA2 Oral cancer: cell lines (mRNA only) & patient tissue samples ↓ ↓ (100) 
SERCA3 Colon cancer: cell lines & patient tissue samples  ↓ (68) 
Breast cancer: patient tissue samples  ↓ (69) 
Secretory pathway calcium ATPases 
SPCA1 Breast cancer: basal-like clinical samples & cell lines ↑  (74) 
SPCA2 Breast cancer: cell lines & patient tissue samples (mRNA only) ↑ ↑* (39) 
↑: increase; ↓: decrease; ↔: no significant difference; *MCF-7 vs MCF-10A 	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